Analysis of drug use in patients with acute coronary syndromes according to standard treatment

Antiplatelet agents, beta-blockers, statins and ACEIs/ARBs are recommended for secondary prevention of recurrent major adverse cardiac events in patients with acute coronary syndromes. A restrospective longittudinal study.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20120000025

Enrollment

1500

Registered

2013-01-16

Start date

2012-07-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndromes Acute coronary syndromes Starndard treatment Analysis drug use

Interventions

Health Services Research

Acute coronary syndromes

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Acute coronary syndromes

Exclusion criteria

Exclusion criteria: No Acute coronary syndromes

Design outcomes

Primary

Measure	Time frame
rationale treatment for secondary prevention in patients with acute coronary syndromes at 12 months Percentage of patients were recieved prescribed drugs according to treatment guideline recommend	—

Secondary

Measure	Time frame
Events at 12 months Major adverse cardiac events	—

Countries

Thailand

Contacts

Public ContactNaowakun Ariyapim

Queen Sirikit Heart Center

yok_bear@yahoo.com081-4899117

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026